360μmol/l corresponded to 343μmol/l. Among the biological parameters tested, only hematocrit impacted capillary uric acid measurements, however negligibly. No medication appeared to significantly affect test results. Plasma uricase measurements were better correlated to ) than capillary measurements (r=0. 84 [0.75-0.90] Background: Gout is a chronic, progressive, inflammatory disease characterised by elevated serum uric acid (sUA) levels (1) . In Europe the prevalence of gout ranges from 0.9-2.5%, and is increasing (2). Published data indicate that gout is an independent risk factor for both all-cause and cardiovascular (CV)-related mortality (3, 4) . Objectives: To conduct a systematic review to identify studies reporting the association between gout and mortality (all-cause and CV-related). Methods: Relevant publications were identified by interrogating electronic databases; Medline & MEDLINE In-Process, EMBASE and the Cochrane Library (accessed 3 May 2016). Eligibility criteria included adult patients with a definitive diagnosis of acute/chronic gout (self-reported/physician diagnosed), with no restriction on publication date, study design or geography. Results: Nineteen studies met the pre-defined inclusion criteria and were reviewed. The studies were conducted in: the US (n=8); Taiwan (n=5); Canada (n=3); Spain (n=1); Singapore (n=1); and the UK (n=1). In addition to patients having a diagnosis of acute/chronic gout, 6 of the 19 studies were conducted in the following patient subgroups: renal transplant (n=1); chronic kidney disease (n=2); patients with a recent acute myocardial infraction (n=2); and patients with heart failure (n=1). There were several consistent finding across the 19 studies: (i) gout was associated with an increase in both all-cause mortality (reported hazard ratios [HR] ranged from 1.13 to 2.37) and CV-related mortality (reported HR ranged from 1.10 to 3.88) compared with patients without gout; (ii) the increased risk in all-cause mortality was primarily driven by an increase in CV-related mortality; (iii) the increased mortality risk was higher in females than males. One study reported that the presence of tophi was independently associated with a higher risk of all-cause mortality. Notably one study reported that patients who received urate-lowering therapy (ULT) have a statistically significant lower all-cause mortality and CV-related mortality risk relative to patients who do not receive ULT. Conclusions: This systematic review confirms that gout is associated with an increased risk of all-cause and CV-related mortality; this was consistently reported across the eligible studies. The findings highlight the risk associated with gout and emphasise the need for appropriate treatment of this curable disease. References: [1] Background: New Caledonia is a Pacific island of 270.000 inhabitants with mixed ethnicities, including Melanesians (39.1%) and Polynesians (10.2%) and people from European ancestry (27.2%). Objectives: To determine the prevalence of gout and hyperuricemia in the various ethnicities and to characterize associated factors. Methods: A 3-degree random sample of the population aged 18 to 60 years old was redressed according to the 2014 New Caledonia census. Face-to-face interviews were performed by trained nurses who used a predefined questionnaire along with planned physical measurements. All participants underwent capillary measurement of creatinine level (StatSensor) and all men and only women older than 40 years underwent uricemia testing (HumaSens). Gout was defined by a validated algorithm (1) . Hyperuricemia was defined by capillary level equivalent to plasma uric acid level (PUA) >6 mg/dl (2) and/or urate lowering drug (ULD) prescription. Results: 1.144 participants (mean age 37.7 years; 50.4% men) were included. Prevalence of gout in the entire redressed sample was 3.3% (95% CI 2.2-4.9). The prevalence was 4.1% (1.8-8.9 ), 2.6% (1.4-4.7), 6.7% (2.5-16.8), and 1.9% (0.5-6.6) for Europeans, Melanesians, Polynesians and other ethnicities, respectively. After adjustment for age and sex, Polynesians showed higher risk for gout than Europeans (adjusted odds ratio [aOR] 4.57 [95% CI 1.3-16.7] ). Prevalence of hyperuricemia, determined in 658 participants, was 67.0% (95% CI 61.9-71.6). Prevalence of hyperuricemia was greater for Polynesians Background: Gout progresses through three stages: hyperuricemia, deposition of monosodium urate (MSU) crystals, and innate immune system response to MSU crystals. Genome wide association studies (GWAS) have provided insight into the molecular control of progression to hyperuricemia. However, less is known about the progression from hyperuricemia to gout. Objectives: To conduct a GWAS for gout (where an immune response to MSU crystals has occurred) using 5,835 cases -the largest GWAS of gout to date. Methods: The GWAS comprised 3 data sets: NZ/Eurogout (2,365 clinicallyascertained cases; 1,485 controls), the Health Professionals Follow-Up (HPFS) and Nurses' Health Studies (NHS) (1,038 cases, self-ascertained using ACR criteria; 1,095 controls), and UK Biobank (2,432 cases, ascertained by self-report of gout, hospital records, and/or use of urate-lowering therapy; 102,989 controls). The NZ/Eurogout samples were genotyped using the Illumina CoreExome v24 bead chip array (547,644 markers), the HPFS/NHS samples using the Illumina OmniExpress v12 bead chip array (730,525 markers), and the UK Biobank samples using an Affymetrix Axiom array (820,967 markers). UK Biobank genotypes had been imputed to ∼73.3M SNPs. Neither the NZ/Eurogout nor NHS/HPFS genotype sets were imputed. Markers common to all three data sets (279,939) were associated with gout (adjusted for sex, age) within each data set separately using PLINK 1.9. An inverse-variance weighted meta-analysis was done with meta v4.4 in R. Results: There were seven loci with genome-wide significant (P<5x10 Background: Calcium pyrophosphate deposition disease (CPPD) and Osteoarthritis (OA) are frequently associated and CPPD with OA is recognized as a clinical subtype [1] . However, the differences in pathogenetic, microscopic and clinical aspects between the two diseases are not clear and how CPPD and OA could affect each other is still a matter of debate. Objectives: To assess the differences between CPPD and OA in terms of anatomic alterations of the joint, evaluated with US, and characteristics of the synovial fluid (SF) of knees affected by CPPD and/or OA. Methods: consecutive patients reaching the outpatient clinic for the presence of knee pain and with any amount of joint effusion were eligible for the study. Patients with diagnosis or suspicion of chronic inflammatory rheumatic conditions were excluded. All enrolled patients underwent US of the knee for the assessment of joint effusion (JE), synovial hypertrophy (SH), synovial power Doppler (PD), femuro-tibial osteophytes (FTO) and alterations of the femoral hyaline cartilage (FHC), using a semiquantitative score (0: normal to 3: severe alteration) and finally a US guided aspiration of the SF. SF was examined by optical and polarized light microscopy to determine total and differential white blood cell (WBC) counts, and for crystal identification. The concentration of the main inorganic ions involved in CPP crystal formation (P 2 O 4-7 , PO 3-4 , Ca 2+ and Mg 2+ ) was assessed by fluorometric and colorimetric assays. CPP crystal detection was also used for the classification of patients. Further, in CPPD patients, a count of the CPP crystals detectable in a single slide was carried out. Depending on the variables, chi-square, Mann Whitney and Spearman Ro tests were used for statistical analysis. Results: 49 patients (28 women), mean age 70.29 yo (SD±10.93) were enrolled in the study; 23 subjects presented OA and 26 CPPD (23.07% acute arthritis, 77.6% CPPD with OA). At US, a statistically significant difference between CPPD and OA was found only for the grade of effusion, being more abundant in CPPD patients. On the contrary, no differences were found regarding SH, PD, FTO, FHC. SF analysis showed that CPPD patients presented a higher volume of SF, a higher total WBC count with a higher polymorphonuclear (PMN) cells percentage and lower monocytes percentage than patients with OA. Further, both total cell count and PMN percentage were positively correlated with the number of crystals in the SF. On the other hand, no statistically significant differences were found in the content of inorganic ions between the two groups. Conclusions: According to these results, patients with CPPD and OA present some distinct features, mainly regarding the characteristics of the SF, compared to patients with OA alone. These differences may reflect different underlying pathogenetic pathways for the two diseases. Surprisingly, the concentration of inorganic ions in the two populations was similar.Further studies are necessary in order to better understand the link between CPPD and OA and the role of ions concentration in the SF for the formation of crystals.
